Skip to main content
PMC home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1985 May 1;161(5):996–1012. doi: 10.1084/jem.161.5.996

Inhibition of plasmacytoma development in BALB/c mice by indomethacin

PMCID: PMC2187607  PMID: 3989472

Abstract

Indomethacin given continuously in the drinking water (20 micrograms/ml) to BALB/cAn pi mice during the latent period of pristane- induced plasmacytoma development dramatically reduced the plasmacytoma incidence from 34.9 to 2.2%. Additionally, indomethacin given from day 0 to 120 or begun as late as 60 d after a single injection of 1.0 ml pristane was also highly effective in reducing the development of plasmacytomas. Indomethacin treatment did not prevent the formation of a peritoneal inflammatory exudate or peritoneal oil granulomatous tissue, although it had a mild inhibitory effect on the intensity of the cellular inflammation, particularly after extensive treatment of greater than 100 d. Indomethacin treatment reduced the incidence of arthritis by 50%. A major effect of indomethacin treatment was a reduction in the appearance of microscopic plasmacytomas that appear in the oil granuloma before plasmacytomas can be detected by routine sampling of the peritoneal exudate. Between days 116 and 181, 16 of 20 mice given 0.5 ml pristane were found to have foci of plasmacytoma cells, while only 2 of 20 indomethacin-treated mice had foci-containing plasmacytoma cells. The number of mice with microscopic foci in the pristane-treated group greatly exceeded the expected incidence of plasmacytomas (22%) at this dose of pristane. The growth of primary plasmacytomas in transplant that is dependent on the pristane- conditioned peritoneal environment was not inhibited by indomethacin treatment. The role of indomethacin in inhibiting plasmacytoma development was not established; two possibilities are that it inhibits production of mutagenic and tissue destructive oxidants by inflammatory cells, and it inhibits prostaglandin synthesis and intracellular production of oxidant biproducts.

Full Text

The Full Text of this article is available as a PDF (2.5 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson P. N., Potter M. Induction of plasma cell tumours in BALB-c mice with 2,6,10,14-tetramethylpentadecane (pristane). Nature. 1969 Jun 7;222(5197):994–995. doi: 10.1038/222994a0. [DOI] [PubMed] [Google Scholar]
  2. Baggiolini M., Schnyder J., Dewald B., Bretz U., Payne T. G. Phagocytosis-stimulated macrophages. Production of prostaglandins and SRS-A, and prostaglandin effects on macrophage activation. Immunobiology. 1982 Apr;161(3-4):369–375. doi: 10.1016/S0171-2985(82)80094-6. [DOI] [PubMed] [Google Scholar]
  3. Bodaness R. S., Chan P. C. Reaction of indomethacin with singlet molecular oxygen. Biochem Pharmacol. 1980 May 15;29(10):1337–1340. doi: 10.1016/0006-2952(80)90427-x. [DOI] [PubMed] [Google Scholar]
  4. Cancro M., Potter M. The requirement of an adherent cell substratum for the growth of developing plasmacytoma cells in vivo. J Exp Med. 1976 Dec 1;144(6):1554–1567. doi: 10.1084/jem.144.6.1554. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cerutti P. A. Prooxidant states and tumor promotion. Science. 1985 Jan 25;227(4685):375–381. doi: 10.1126/science.2981433. [DOI] [PubMed] [Google Scholar]
  6. Ceuppens J. L., Goodwin J. S. Endogenous prostaglandin E2 enhances polyclonal immunoglobulin production by tonically inhibiting T suppressor cell activity. Cell Immunol. 1982 Jun;70(1):41–54. doi: 10.1016/0008-8749(82)90131-9. [DOI] [PubMed] [Google Scholar]
  7. Chouaib S., Chatenoud L., Klatzmann D., Fradelizi D. The mechanisms of inhibition of human IL 2 production. II. PGE2 induction of suppressor T lymphocytes. J Immunol. 1984 Apr;132(4):1851–1857. [PubMed] [Google Scholar]
  8. Emerit I., Cerutti P. A. Tumor promoter phorbol 12-myristate 13-acetate induces a clastogenic factor in human lymphocytes. Proc Natl Acad Sci U S A. 1982 Dec;79(23):7509–7513. doi: 10.1073/pnas.79.23.7509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Emerit I., Cerutti P. A. Tumour promoter phorbol-12-myristate-13-acetate induces chromosomal damage via indirect action. Nature. 1981 Sep 10;293(5828):144–146. doi: 10.1038/293144a0. [DOI] [PubMed] [Google Scholar]
  10. Emerit I., Levy A., Cerutti P. Suppression of tumor promoter phorbolmyristate acetate-induced chromosome breakage by antioxidants and inhibitors of arachidonic acid metabolism. Mutat Res. 1983 Aug;110(2):327–335. doi: 10.1016/0027-5107(83)90149-5. [DOI] [PubMed] [Google Scholar]
  11. Flescher E., Gonen P., Keisari Y. Oxidative burst-dependent tumoricidal and tumorostatic activities of paraffin oil-elicited mouse macrophages. J Natl Cancer Inst. 1984 Jun;72(6):1341–1347. [PubMed] [Google Scholar]
  12. Fulton A. M. In vivo effects of indomethacin on the growth of murine mammary tumors. Cancer Res. 1984 Jun;44(6):2416–2420. [PubMed] [Google Scholar]
  13. Goodwin J. S., Bankhurst A. D., Messner R. P. Suppression of human T-cell mitogenesis by prostaglandin. Existence of a prostaglandin-producing suppressor cell. J Exp Med. 1977 Dec 1;146(6):1719–1734. doi: 10.1084/jem.146.6.1719. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Goodwin J. S. Prostaglandin synthetase inhibitors as immunoadjuvants in the treatment of cancer. J Immunopharmacol. 1980;2(4):397–424. doi: 10.3109/08923978009026403. [DOI] [PubMed] [Google Scholar]
  15. Hemler M., Lands W. E. Purification of the cyclooxygenase that forms prostaglandins. Demonstration of two forms of iron in the holoenzyme. J Biol Chem. 1976 Sep 25;251(18):5575–5579. [PubMed] [Google Scholar]
  16. Humes J. L., Bonney R. J., Pelus L., Dahlgren M. E., Sadowski S. J., Kuehl F. A., Jr, Davies P. Macrophages synthesis and release prostaglandins in response to inflammatory stimuli. Nature. 1977 Sep 8;269(5624):149–151. doi: 10.1038/269149a0. [DOI] [PubMed] [Google Scholar]
  17. Kuehl F. A., Jr, Humes J. L., Egan R. W., Ham E. A., Beveridge G. C., Van Arman C. G. Role of prostaglandin endoperoxide PGG2 in inflammatory processes. Nature. 1977 Jan 13;265(5590):170–173. doi: 10.1038/265170a0. [DOI] [PubMed] [Google Scholar]
  18. Kurland J. I., Bockman R. Prostaglandin E production by human blood monocytes and mouse peritoneal macrophages. J Exp Med. 1978 Mar 1;147(3):952–957. doi: 10.1084/jem.147.3.952. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Kurland J. I., Kincade P. W., Moore M. A. Regulation of B-lymphocyte clonal proliferation by stimulatory and inhibitory macrophage-derived factors. J Exp Med. 1977 Nov 1;146(5):1420–1435. doi: 10.1084/jem.146.5.1420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Kurland J., Moore M. A. Modulation of hemopoiesis by prostaglandins. Exp Hematol. 1977 Sep;5(5):357–373. [PubMed] [Google Scholar]
  21. Leak L. V. Interaction of mesothelium to intraperitoneal stimulation. I. Aggregation of peritoneal cells. Lab Invest. 1983 Apr;48(4):479–491. [PubMed] [Google Scholar]
  22. Lydyard P. M., Brostoff J., Hudspith B. N., Parry H. Prostaglandin E2-mediated enhancement of human plasma cell differentiation. Immunol Lett. 1982 Mar;4(3):113–116. doi: 10.1016/0165-2478(82)90020-7. [DOI] [PubMed] [Google Scholar]
  23. Mandel M. A., DeCosse J. J. The effects of heterologous antithymocyte sera in mice. V. Enhancement of plasma cell tumor induction. J Immunol. 1972 Aug;109(2):360–365. [PubMed] [Google Scholar]
  24. Miyamoto T., Ogino N., Yamamoto S., Hayaishi O. Purification of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. J Biol Chem. 1976 May 10;251(9):2629–2636. [PubMed] [Google Scholar]
  25. Mokyr M. B., Dray S. Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide. Cancer Res. 1983 Jul;43(7):3112–3119. [PubMed] [Google Scholar]
  26. Narisawa T., Satoh M., Sano M., Takahashi T. Inhibition of initiation and promotion by N-methylnitrosourea-induced colon carcinogenesis in rats by non-steroid anti-inflammatory agent indomethacin. Carcinogenesis. 1983 Oct;4(10):1225–1227. doi: 10.1093/carcin/4.10.1225. [DOI] [PubMed] [Google Scholar]
  27. Ohno S., Migita S., Wiener F., Babonits M., Klein G., Mushinski J. F., Potter M. Chromosomal translocations activating myc sequences and transduction of v-abl are critical events in the rapid induction of plasmacytomas by pristane and abelson virus. J Exp Med. 1984 Jun 1;159(6):1762–1777. doi: 10.1084/jem.159.6.1762. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. POTTER M., BOYCE C. R. Induction of plasma-cell neoplasms in strain BALB/c mice with mineral oil and mineral oil adjuvants. Nature. 1962 Mar 17;193:1086–1087. doi: 10.1038/1931086a0. [DOI] [PubMed] [Google Scholar]
  29. POTTER M., MACCARDLE R. C. HISTOLOGY OF DEVELOPING PLASMA CELL NEOPLASIA INDUCED BY MINERAL OIL IN BALB/C MICE. J Natl Cancer Inst. 1964 Sep;33:497–515. [PubMed] [Google Scholar]
  30. Padarathsingh M. L., Dean J. H., McCoy J. L., Lewis D. D., Northing J. W., Natori T., Law L. W. Cell-mediated immunity against particulate and solubilized tumor-associated antigens of murine plasmacytomas detected by macrophage migration inhibition assays. Int J Cancer. 1977 Oct 15;20(4):624–631. doi: 10.1002/ijc.2910200421. [DOI] [PubMed] [Google Scholar]
  31. Pekoe G., Van Dyke K., Peden D., Mengoli H., English D. Antioxidation theory of non-steroidal anti-inflammatory drugs based upon the inhibition of luminol-enhanced chemiluminescence from the myeloperoxidase reaction. Agents Actions. 1982 Jul;12(3):371–376. doi: 10.1007/BF01965406. [DOI] [PubMed] [Google Scholar]
  32. Pick E., Keisari Y. Superoxide anion and hydrogen peroxide production by chemically elicited peritoneal macrophages--induction by multiple nonphagocytic stimuli. Cell Immunol. 1981 Apr;59(2):301–318. doi: 10.1016/0008-8749(81)90411-1. [DOI] [PubMed] [Google Scholar]
  33. Plescia O. J., Smith A. H., Grinwich K. Subversion of immune system by tumor cells and role of prostaglandins. Proc Natl Acad Sci U S A. 1975 May;72(5):1848–1851. doi: 10.1073/pnas.72.5.1848. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Potter M., Pumphrey J. G., Walters J. L. Growth of primary plasmacytomas in the mineral oil-conditioned peritoneal environment. J Natl Cancer Inst. 1972 Jul;49(1):305–308. [PubMed] [Google Scholar]
  35. Potter M., Walters J. L. Effect of intraperitoneal pristane on established immunity to the adj-PC-5 plasmacytoma. J Natl Cancer Inst. 1973 Sep;51(3):875–881. doi: 10.1093/jnci/51.3.875. [DOI] [PubMed] [Google Scholar]
  36. Potter M., Wax J. S. Genetics of susceptibility to pristane-induced plasmacytomas in BALB/cAn: reduced susceptibility in BALB/cJ with a brief description of pristane-induced arthritis. J Immunol. 1981 Oct;127(4):1591–1595. [PubMed] [Google Scholar]
  37. Potter M., Wax J. S. Peritoneal plasmacytomagenesis in mice: comparison of different pristane dose regimens. J Natl Cancer Inst. 1983 Aug;71(2):391–395. [PubMed] [Google Scholar]
  38. Röllinghoff M., Rouse B. T., Warner N. L. Tumor immunity to murine plasma cell tumors. I. Tumor-associated transplantation antigens of NZB and BALB-c plasma cell tumors. J Natl Cancer Inst. 1973 Jan;50(1):159–172. doi: 10.1093/jnci/50.1.159. [DOI] [PubMed] [Google Scholar]
  39. Scott W. A., Zrike J. M., Hamill A. L., Kempe J., Cohn Z. A. Regulation of arachidonic acid metabolites in macrophages. J Exp Med. 1980 Aug 1;152(2):324–335. doi: 10.1084/jem.152.2.324. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Snyder D. S., Beller D. I., Unanue E. R. Prostaglandins modulate macrophage Ia expression. Nature. 1982 Sep 9;299(5879):163–165. doi: 10.1038/299163a0. [DOI] [PubMed] [Google Scholar]
  41. Solanki V., Rana R. S., Slaga T. J. Diminution of mouse epidermal superoxide dismutase and catalase activities by tumor promoters. Carcinogenesis. 1981;2(11):1141–1146. doi: 10.1093/carcin/2.11.1141. [DOI] [PubMed] [Google Scholar]
  42. Takakura K., Mason W. B., Hollander V. P. Studies on the pathogenesis of plasma cell tumors. I. Effect of cortisol on development of plasma cell tumors. Cancer Res. 1966 Apr;26(4):596–599. [PubMed] [Google Scholar]
  43. Thompson P. A., Jelinek D. F., Lipsky P. E. Regulation of human B cell proliferation by prostaglandin E2. J Immunol. 1984 Nov;133(5):2446–2453. [PubMed] [Google Scholar]
  44. Verma A. K., Ashendel C. L., Boutwell R. K. Inhibition by prostaglandin synthesis inhibitors of the induction of epidermal ornithine decarboxylase activity, the accumulation of prostaglandins, and tumor promotion caused by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res. 1980 Feb;40(2):308–315. [PubMed] [Google Scholar]
  45. WHISSON M. E., CONNORS T. A. DRUG-INDUCED REGRESSION OF LARGE PLASMA CELL TUMOURS. Nature. 1965 Jan 23;205:406–406. doi: 10.1038/205406a0. [DOI] [PubMed] [Google Scholar]
  46. Weitberg A. B., Weitzman S. A., Destrempes M., Latt S. A., Stossel T. P. Stimulated human phagocytes produce cytogenetic changes in cultured mammalian cells. N Engl J Med. 1983 Jan 6;308(1):26–30. doi: 10.1056/NEJM198301063080107. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES